Prelude Therapeutics Inc — Director's Dealing 2021

Dec 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Prelude Therapeutics Inc (PRLD)
CIK: 0001678660
Period of Report: 2021-12-13

Reporting Person: Combs Andrew (EVP, Head of Chemistry)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-13	Common Stock	P	4000	$12.12	Acquired	264380	Direct
2021-12-14	Common Stock	P	4000	$11.60	Acquired	268380	Direct

Footnotes

F1: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.